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Background: PKCδ expressed in neutrophils is implicated in promoting reperfusion injury after ischemic stroke. To
understand the molecular and cellular actions of PKCδ, we employed a chemical-genetics approach to identify
PKCδ substrates in neutrophils.
Results: We recently generated knock-in mice endogenously expressing analog-specific PKCδ (AS-PKCδ) that can
utilize ATP analogs as phosphate donors. Using neutrophils isolated from the knock-in mice, we identified several
PKCδ substrates, one of which was lipocalin-2 (LCN2), which is an iron-binding protein that can trigger apoptosis by
reducing intracellular iron concentrations. We found that PKCδ phosphorylated LCN2 at T115 and this phosphorylation
was reduced in Prkcd−/− mice. PKCδ colocalized with LCN2 in resting and stimulated neutrophils. LCN2 release from
neutrophils after cerebral ischemia was reduced in PKCδ null mice.
Conclusions: These findings suggest that PKCδ phosphorylates LCN2 and mediates its release from neutrophils during
ischemia-reperfusion injury.
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Ischemic stroke is a leading cause of mortality and disability
in the United States [1]. Early reperfusion with thrombo-
lytic agents can be effective in treating acute ischemic
stroke, but may initiate and enhance inflammatory re-
sponses causing reperfusion injury [2]. After reperfusion,
neutrophils adhere to cerebral vasculature, infiltrate ische-
mic brain tissues, and release free radicals and proteins that
may exacerbate brain injury [3]. Our prior work indicates
that PKCδ is necessary for neutrophil activation following
ischemia and reperfusion. We found that Prkcd−/− mice
show a striking 70% reduction in brain injury after ischemic
stroke [4]. This outcome was associated with reduced infil-
tration of neutrophils into infarcted tissue, as well as im-
paired neutrophil adhesion, migration, respiratory burst,
and degranulation. To further understand the molecular
and cellular mechanisms by which PKCδ contributes to* Correspondence: wchou2@kent.edu
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neutrophils.
PKC constitutes a family of 10 serine-threonine ki-
nases sharing a highly conserved catalytic domain [5].
Similarities in the catalytic domains of PKC isozymes
make it difficult to identify the unique targets of an indi-
vidual isozyme in the presence of related cellular kinases.
A chemical-genetic approach has been developed to
identify kinase substrates and specific kinase inhibitors
by modifying the gatekeeper residue of catalytic domain
to accept analogs of ATP and PP1 inhibitors that have
low affinity for native kinases [6,7]. Using this approach
we generated and characterized an analog-specific PKCδ
(AS-PKCδ) [8-10]. AS-PKCδ shows kinase activity simi-
lar to wild type PKCδ, but can utilize N6-(benzyl)-ATP
as a phosphate donor and is uniquely sensitive to inhib-
ition by 1NA-PP1 [8-10]. To identify PKCδ substrates in
neutrophils, we wanted to express AS-PKCδ in neutro-
phils, but because they are terminally differentiated and
difficult to transfect, we instead used AS-PKCδ knock-in
mice, which endogenously express AS-PKCδ [10]. Using
neutrophils isolated from these knock-in mice, we
identified lipocalin-2 (LCN2) as a PKCδ substrate.
LCN2, also known as oncogene 24p3, siderocalin orThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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initially purified as a 25 kDa protein secreted from neutro-
phils [11]. Several pathological conditions including bac-
terial infection [12], renal ischemia [13], spinal cord injury
[14], and ischemic stroke [15-17] trigger the release of
LCN2. Here we found reduced release of LCN2 in
Prkcd−/− mice following cerebral ischemia, indicating
an important role for PKCδ in LCN2 secretion.
Methods
Kinase assay
Neutrophils were isolated from bone marrow by Percoll
density gradient centrifugation [4,18]. Neutrophils were
lysed by freeze/thaw treatment in modified RIPA buffer
containing 50 mM Tris–HCl pH 7.4, 150 mM NaCl, 1%
NP-40, 5 mM EDTA, 5 mM EGTA, phosphatase inhibi-
tor cocktails I and II (Sigma-Aldrich), and cOmpleteTM
protease inhibitor cocktail (Roche), and were centrifuged
at 20,000 g for 15 min at 4°C. The supernatant (100 μg
proteins) was incubated in 60 μl of PKC reaction buffer
containing 20 mM HEPES pH 7.4, 0.1 mM EGTA,
0.03% Triton X-100, and 10 mM MgCl2 at 27°C for
30 min with 1 mM GTP, 200 μM N6-(benzyl)-ATP-γS
(Biolog), and 1 μM phorbol 12-myristate 13-acetate (PMA)
(Sigma-Aldrich) to initiate the reaction. Control reac-
tions without PMA, and reactions with 1 μM 1NA-PP1
(Calbiochem) to inhibit AS-PKCδ activity were included.
The kinase reactions were stopped by adding 20 mM
EDTA. Thiophosphorylated proteins were alkylated by in-
cubation with 2.5 mM para-nitrobenzylmesylate (PNBM)
(Epitomics) for 2 h at room temperature.
Fractionation by MicroSol-IEF
Alkylated proteins were resolved by isoelectric focusing
using a Zoom-IEF Fractionator (Invitrogen), according
to the manufacturer’s protocol [19]. Alkylated samples
were dissolved in IEF fractionation buffer containing
7 M urea, 2 M thiourea, 4% CHAPS (Invitrogen), 65 mM
DTT, 1 mM EDTA, protease inhibitors cocktail (Roche),
and 1 mM PMSF (Sigma-Aldrich), and centrifuged at
20,000 g for 60 min at 4°C. The supernatant was collected
to determine the protein concentration by the Bradford
protein assay using BSA as a standard and were ad-
justed with IEF fractionation buffer to 0.6 mg/mL. Aliquots
of 650 μl were loaded in five different pH chambers
(pH 3.0-4.6, pH 4.6-5.4, pH 5.4-6.2, pH 6.2-7.0, and
pH 7.0-10.0) in the Zoom-IEF Fractionator, and proc-
essed sequentially at 100 V for 20 min, 200 V for 80 min
and 600 V for 80 min. The fractionated samples from
each chamber were analyzed by western blot analysis
using rabbit monoclonal antibodies against the thio-
phosphate esters (1:10,000 dilution; Abcam) and HRP
conjugated secondary antibodies (1:1,000 dilution; Jackson
ImmunoResearch). Gel loading was assessed by westernblot analysis with a mouse monoclonal anti-actin antibody
(1:2,000 dilution; Sigma-Aldrich).
MALDI-TOF mass spectrometry for protein identification
Protein bands of interest detected on western blots were
excised from parallel Coomassie Blue stained gels and
placed into microcentrifuge tubes. The gel slices were
dried in a vacuum concentrator, rehydrated and digested
in trypsin solution (12.5 ng/μl sequencing grade trypsin
in freshly diluted 25 mM ammonium bicarbonate) over-
night at 32°C. The liquid containing trypsinized peptides
was extracted twice with 50 μl of 50% acetonitrile/2%
TFA. The combined extracts were dried and resuspended
in matrix solution (10 mg/ml 4-hydroxy-α-cyanocinnamic
acid in 50% acetonitrile/0.1% TFA). Matrix-Assisted
Laser Desorption/Ionization Time-of-Flight (MALDI-TOF)
mass spectrometric analysis was performed on the digest
using a PerSeptive Voyager DE-RP mass spectrometer in the
linear mode by Applied Biomics, Hayward, CA. Detected
peptides were analyzed by peptide mass fingerprinting using
the Mascot search engine [20].
Purification of recombinant LCN2
A plasmid (kindly provided by M. Green, U. Mass. Med.
School) containing the cDNA sequence encoding the mouse
Lcn2 gene in pGEX-2T (GE Healthcare) was expressed in
E. coli BL21(DE3)pLysS cells (Invitrogen) [21]. GST-LCN2
fusion protein was purified by affinity chromatography
using Glutathione-Sepharose 4B beads (GE Healthcare).
Purified GST-LCN2 was incubated with thrombin-agarose
(Sigma-Aldrich) to remove the GST tag. The supernatant
containing cleaved GST and LCN2 was incubated with
Glutathione-Sepharose to absorb the GST. The super-
natant containing only LCN2 was collected for in vitro
kinase assays.
In vitro kinase assay
In vitro phosphorylation of purified LCN2 by recombin-
ant PKCδ (Invitrogen) was performed as described [22].
The kinase reaction was initiated at 37°C by adding re-
combinant LCN2 and [γ-32P]ATP. At different time points,
the reaction mixture was stopped by the addition of SDS
sample buffer. Proteins were separated on NuPAGE
Bis-Tris gels (Invitrogen) and stained using SimplyBlue
(Invitrogen). Phosphorylated LCN2 was detected by
phosphorimaging (Typhoon 9410, Amersham Bioscience).
Mapping phosphorylation sites by tandem mass
spectrometry
To identify the PKCδ phosphorylation sites, LCN2 pro-
tein was phosphorylated in vitro by PKCδ using 0.5 mM
non-radiolabeled ATP for 4 h as described above. The
reaction mixtures were fractionated by SDS-PAGE and
stained with SimplyBlue (Invitrogen). Gel slices containing
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the resulting peptide mixtures were analyzed by nano-
liquid chromatography-mass spectrometry/mass spectrom-
etry (nano-LC-MS/MS) serviced at the Protein Chemistry
Center, UT Southwestern Medical Center. Samples from
the digests were analyzed by nano-LC-MS/MS using a
LC-Packings HPLC (Dionex) coupled to a QStar XL mass
spectrometer (Applied Biosystems). Data were searched
against a home-built database that includes the LCN2
sequence. Four modifications were included in the data-
base search: carbamidomethyl (C), oxidation (M), phospho
(ST), and phospho (Y).
Generation of LCN2 phosphorylation site mutants
LCN2 T115A was generated by site-directed mutagen-
esis using a QuikChange mutagenesis kit (Stratagene).
The mouse Lcn2 cDNA subcloned into pGEX-2TK was
used as a template to replace Thr-115 with Ala using the
following primers: 5′-GCTCCAGGGCTGGCCAGTTC
GCCCTGGGAAATATGCACAGG-3′ (forward) and 5′-C
CTGTGCATATTTCCCAGGGCGAACTGGCCAGCCC
TGGAGC-3′ (reverse). The coding region was sequenced
to confirm error-free PCR and the T115A mutation. The
LCN2 T115A protein was generated in E. coli BL21(DE3)
pLysS cells and purified as described above.
Detection of LCN2 T115 phosphorylation by phospho-specific
antibody
A polyclonal rabbit anti-phospho-LCN2 (T115) antibody
against a phosphopeptide 110RAGQF[pT]LGNMHR121
was generated and affinity-purified as a service at ProSci
Inc. We optimized specificity for the targeted phospho-
epitope using both negative and positive affinity purifica-
tion methods, as described [23]. The phospho-LCN2
(T115) antibody (1:500 dilution) was used in western
blotting to detect the phosphorylation of LCN2 in neu-
trophil lysates or LCN2 phosphorylated in vitro by PKCδ
in the presence of non-radioactive ATP.
Immunofluorescence
Neutrophils were plated on glass coverslips coated with
20% fetal calf serum for 10 min at 37°C. The coverslips
with attached neutrophils were treated with or without
1 μM formyl-Met-Leu-Phe (fMLP) for 10 min at 37°C
and fixed in 2% paraformaldehyde in PBS for 10 min at
room temperature [24]. After permeabilization in 0.1%
Triton X-100 in PBS for 5 min, neutrophils were blocked
in 10% normal donkey serum (NDS), 0.2% BSA in PBS
for 1 h and incubated with mouse anti-PKCδ antibody
(1:200 dilution; BD) and goat anti-LCN2 antibody (1:200
dilution; R&D Systems) diluted in PBS containing 2%
NDS and 0.2% BSA overnight at 4°C. After three washes
with PBS, neutrophils were incubated with the appropriate
Donkey fluorochrome-conjugated secondary antibodies(1:200 dilution; Jackson ImmunoResearch) and cover-
slipped in mounting media containing DAPI (Vector
Labs) to localize nuclei. Images were captured using
Zeiss LSM 510 laser confocal microscope.
Secretion of LCN2 in neutrophils
Neutrophils were stimulated with 1 μM of fMLP
(Sigma-Aldrich) for 10, 20, 30, 60, and 120 min. Release
and cell-associated LCN2 were analyzed by western blot
analysis using anti-LCN2 antibody (R&D Systems).
Cerebral ischemia and reperfusion
Global cerebral ischemia was induced by bilateral common
carotid artery occlusion (BCCAO) without hypotension
[25,26]. Mice weighing 25–35 g were anesthetized with
1.5% isoflurane in 30% O2/70% N2 using the V-10
Anesthesia system (VetEquip). Rectal temperature was
maintained at 37 ± 0.5°C throughout the procedure by
the TR-200 homeothermic temperature system (Fine
Science Tools). Both common carotid arteries were care-
fully dissected away from the vagus nerves and occluded
with Micro Serrefines (Fine Science Tools). Following
10 min of occlusion, the Micro Serrefines were removed
from the CCA to induce reperfusion. All procedures were
conducted in accordance with Institutional Animal Care
and Use Committee policies.
Collection of mouse serum
At different time points after BCCAO, mice were anes-
thetized with 5% isoflurane and euthanized by cervical
dislocation. The blood was collected from the decapi-
tated trunk and placed at room temperature for one
hour. The blood was centrifuged at 2000 g for 20 min at
room temperature, and the supernatant was collected as
blood serum for western blot analysis [27].
Statistical analysis
Quantitative data were expressed as mean ± SEM and
analyzed using Prism 5.0 (GraphPad). Two-tailed, unpaired
t-test or ANOVA with post hoc tests was used to deter-
mine statistical significance between means. The value of
p less than 0.05 was considered to be statistically significant.
Results
Identification of PKCδ substrates in neutrophils
We found that only AS-PKCδ, but not wild type PKCδ,
can use N6-(benzyl)-ATP in a kinase reaction with histone
III as a substrate [8]. Previous studies have demonstrated
the use of analog-specific kinases to identify substrates
with 32P-labeled ATP analogs [28-33]. However, it remains
challenging to isolate 32P-labeled substrates through con-
ventional chromatography for identification by mass spec-
trometry. To facilitate the identification and purification
of PKCδ substrates, we adopted an affinity tagging strategy
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antibody [8]. First, an analog-specific kinase is used to
thiophosphorylate substrates with N6-(benzyl)-ATP-γS.
The thiophosphate groups are then alkylated by para-
nitrobenzylmesylate (PNBM) to create thiophosphate
ester epitopes that can be detected with the antibody.
Using this method, we found several proteins were la-
beled in AS-PKCδ neutrophil lysates, but not in wild
type lysates (Figure 1A). We purified some of these puta-
tive substrates by microscale solution isoelectric focusing
(MicroSol-IEF) [19] and SDS-PAGE (Figure 1B and C).
Coomassie blue–stained bands (Figure 1C) that matched
immunoreactive bands (Figure 1B) were excised, and
proteins in excised gels were identified by MALDI-TOF
peptide mass fingerprint analysis. After a careful literature
search to study known functions of these potential sub-
strates and evaluate their potential contribution to under-
standing the role of PKCδ in stroke-induced reperfusion
injury, we decided to focus on LCN2, a 25 kDa protein
band identified in the fraction of pI 7–10 (Figure 1C).
Previous studies have shown that LCN2 plays a vital
role in apoptosis [21,34] and the plasma concentration
of LCN2 is elevated in patients suffering from ischemic
stroke [15-17]. Understanding the role of PKCδ-LCN2
signaling events may reveal an unidentified neural-
immune interaction contributing to the induction of
neuronal apoptosis.
Identification of LCN2 T115 as the PKCδ phosphorylation site
To investigate whether LCN2 is a direct substrate of
PKCδ, we prepared recombinant LCN2 (Figure 2) andFigure 1 Identification and purification of PKCδ substrates in neutrop
putative PKCδ substrates in neutrophil lysates from AS-PKCδ knock-in (KI) m
samples as a loading control. (B, C) Identification of PKCδ substrates by Mi
were incubated with PMA and N6-(benzyl)-ATP-γS, and then thiophosphoryla
focusing in 5 pools as shown. The proteins fractionated before (bf IEF) a
to western blot analysis using anti-thiophosphate ester antibody (B) and the
bands that matched with the immunoreactive bands were excised for analys
pI pool that was identified as LCN2.found that PKCδ phosphorylated LCN2 efficiently in
in vitro kinase assays (Figure 3A). Nano-LC-MS/MS
analysis of the phosphorylated and trypsin digested
LCN2 identified a single phosphorylated peptide containing
a threonine residue at 115 (in italics) (AGQFTLGNMHR;
amino acids 111–121) (Figure 3B and C). To verify the
PKCδ phosphorylation site, we generated a phosphorylation
site mutant by mutating Thr-115 into Ala (T115A) and
found that the T115A mutant is not phosphorylated by
PKCδ (Figure 3D). A ribbon model of LCN2 (PDB number:
1X89) was generated using UCSF Chimera (http://www.cgl.
ucsf.edu/chimera), and predicted that T115 is located in the
solvent-accessible β5 strand (Figure 3E) [35]. T115 and
surrounding residues are well conserved between hu-
man, rat, and mouse homologs of LCN2 (Figure 3 F)
[36], suggesting a conserved role in function.
Phosphorylation of LCN2 at T115 is reduced in neutrophils
from Prkcd−/− mice
After identification of the PKCδ phosphorylation site
in vitro (Figure 3), we investigated whether PKCδ phos-
phorylates LCN2 in vivo. We prepared an affinity-purified,
phospho-specific antibody raised against a peptide con-
taining phospho-T115. This anti-phospho-LCN2 (T115)
antibody specifically detected recombinant LCN2 phos-
phorylated by PKCδ in vitro, but not unphosphorylated
LCN2 or LCN2 T115A (Figure 4A). Anti-phospho-
LCN2 (T115) immunoreactivity was reduced by 25% in
Prkcd−/− neutrophils compared with wild type neutrophils
(Figure 4B and C), consistent with the prediction that
PKCδ phosphorylates neutrophil LCN2 at T115 in vivo.hils. (A) Western blot with anti-thiophosphate ester antibody showing
ice. The bottom panel shows β-actin immunoreactivity in the same
croSol-IEF purification and mass spectrometry. AS-PKCδ neutrophil lysates
ted proteins were alkylated with PNBM and separated by isoelectric
nd after IEF were separated on parallel gels, one of which was subjected
other stained with Coomassie Blue (C). The Coomassie-stained protein
is by mass spectrometry. The arrows indicate a protein band in the 7–10
Figure 2 Purification of LCN2. (A) Recombinant GST-LCN2 was purified from E. coli BL21 by affinity chromatography using glutathione-sepharose 4B.
Lysates from different purification steps were separated by SDS-PAGE: before (Bf) and after (Af) IPTG induction, supernatant after centrifugation (S),
flow-through from column after loading supernatant (FT), 1st column wash (W1), 2nd column wash (W2), and elution of GST-LCN2 (E). (B) GST-LCN2
was digested by thrombin to remove the GST tag. GST-LCN2 was incubated with Thrombin-agarose (Sigma) at RT for up to 4 h. After 4 h incubation, the
cleaved GST was absorbed by glutathione-sepharose. The supernatant containing only LCN2 (4 h*) was collected.
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Since the integrity of subcellular compartments is lost
during the preparation of cell lysates, it is important to
demonstrate the colocalization of kinase and substrate
in intact cells [37]. We performed immunofluorescence
staining of neutrophils using antibodies against PKCδ
and LCN2 (Figure 5). At baseline, PKCδ and LCN2 were
diffusely distributed in the cell. Upon exposure to the
fMLP chemoattractant, neutrophils took on a polarized
morphology and initiated migration with F-actin enriched
at the leading edge [38,39]. PKCδ was found mostly in the
leading edge of polarized neutrophils [40] and LCN2 was
detected at both poles. PKCδ and LCN2 colocalized with
F-actin at the leading edge. The subcellular localization of
LCN2 was previously determined by electron microscopic
immunocytochemistry at high resolution, showing that
LCN2 is present in the secondary vesicles (granules) and
cytosol of neutrophils [41]. The presence of LCN2 in two
different compartments is probably because LCN2 is a
relatively small molecule (25 kDa) and can leak from
vesicles (granules) into the cytosol [41]. PKCδ has been
detected in the cytosol of neutrophils [42] as well as
in granule fractions after stimulation with opsonized
zymosan [43]. Based on previous studies and our current
findings, we think that the colocalization of PKCδ and
LCN2 supports their relationship as kinase and substrate
in neutrophils.Release of LCN2 from neutrophils and after cerebral ischemia
is reduced in Prkcd−/− mice
Previous studies demonstrated that the level of LCN2 in
human plasma is elevated after ischemic stroke [15-17].
Since peripheral blood neutrophils are activated during
the first few hours after stroke [2,44], the elevated LCN2in plasma is likely derived from activated neutrophils.
We previously found that several measures of neutrophil
activation are impaired in neutrophils from Prkcd−/−
mice [4]. We therefore hypothesized that LCN2 secretion
would be impaired as well. To induce LCN2 secretion
in vitro, we treated neutrophils with fMLP and found that
the fMLP-stimulated release of LCN2 was reduced in
Prkcd−/− neutrophils (Figure 6A). This result could not be
explained by reduced abundance of LCN2, since LCN2
abundance was similar in wild type and Prkcd−/− neutro-
phils (Figure 6A), suggesting that PKCδ is involved in
regulating the secretion but not the expression of LCN2.
We then examined the level of LCN2 in the sera of
wild type and Prkcd−/− mice after global cerebral ische-
mia (Figure 6B). Blood sera collected at different inter-
vals after 10 min of bilateral common carotid artery
occlusion (BCCAO) were subjected to western blot
analysis for LCN2. The abundance of LCN2 immuno-
reactivity was low in the sera of mice not subjected to
BCCAO. In wild type mice, the level of LCN2 increased
one hour after BCCAO, and increased progressively
further at 4 and 24 hours. LCN2 induction after BCCAO
was greatly reduced in Prkcd−/− mice, indicating a role of
PKCδ in mediating LCN2 release after cerebral ischemia.Discussion
In this study, we employed a chemical-genetics approach
to identify PKCδ substrates in neutrophils. One of the
PKCδ substrates was LCN2, a member of the lipocalin
family. PKCδ directly phosphorylates LCN2 at T115
in vitro and in neutrophils. The members of lipocalin
family share little overall sequence homology, but all
form a similar cup-shaped structure suited for carrying
small hydrophobic molecules [36]. The crystal structure
Figure 3 PKCδ phosphorylates LCN2 at T115 in vitro. (A) Recombinant LCN2 proteins were subjected to in vitro kinase assays by PKCδ for up
to 4 h. Representative autoradiographs of phosphorylated LCN2 (P-LCN2) are shown in the upper panel. Scanned images of Coomassie blue-
stained gels (LCN2) are in the lower panel. (B) Analysis of LCN2 phosphorylation by PKCδ using mass spectrometry. LCN2 was phosphorylated by
PKCδ and digested with trypsin. Fragments identified by nano-LC-MS/MS are underlined. The phosphorylated form of peptide AGQF[T]LGNMHR
(in bold, amino acids 111–121) was detected. (C) Mass spectrometry spectrum. Identification of the phosphopeptide AGQF[T]LGNMHR (Mr = 1326.57,
m/z = 615.33) by tandem MS indicating that the peptide was phosphorylated at T115. (D) Recombinant LCN2 T115A proteins were subjected to
in vitro kinase assays by PKCδ for up to 4 h. (E) Crystal structure of LCN2 containing a siderophore (colored by atom type, N = blue, C = black, O = red)
and an iron (orange). T115 with side chain shown is located in the β5 strand. (F) Sequence surrounding T115 (highlighted in red) from human, rat, and
mouse LCN2 homologs. Conserved amino acids are surrounded by black boxes.
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funnel-like binding pocket containing an iron-loaded
siderophore [35] (Figure 3E). The PKCδ phosphorylation
site (T115) is not located within the siderophore-binding
pocket, but on the β5 strand with its side chain project-
ing outward. Thus, phosphorylation of T115 is unlikely
to alter the binding with the siderophore, but instead
could regulate the interaction of LCN2 with other
molecules.
The anti-phospho-LCN2 (T115) immunoreactivity was
significantly reduced in the neutrophil lysates of Prkcd −/−
mice (Figure 4). However, the presence of residual immu-
noreactivity in Prkcd −/− mice suggests that T115 mightalso be phosphorylated by other kinases. There are three
additional PKC isozymes (α, β, ζ) found expressed in neu-
trophils [4,42,43]. The preferred amino acid sequences
flanking the phosphorylated residue for each PKC isozyme
have been determined as isozyme specific phosphorylation
motifs [45,46]. The four PKC isozymes (α, β, δ, ζ) in neu-
trophils all prefer phosphorylating peptides with a hydro-
phobic residue at position +1 of the phosphorylated site
towards the carboxyl-terminal [45,46]. The amino acid fol-
lowing Thr-115 of LCN2 fits that criterion with Leu at this
position (Figure 3B). PKCα and δ, but not PKCβ and ζ,
prefer Arg at −5 position. Only PKCδ, but not other
neutrophil PKC’s, prefers hydrophobic residues at +2, +3
Figure 4 PKCδ phosphorylation of LCN2 at T115 is reduced in
neutrophils from Prkcd−/− mice. (A) An affinity-purified rabbit
anti-phospho-LCN2 (T115) antibody detected PKCδ phosphorylation of
recombinant LCN2 (P), but not unphosphorylated LCN2 (N). The antibody
was not immunoreactive against the LCN2 T115A mutant before or after
incubation with PKCδ. (B) Representative western blot showing less
immunoreactivity with the phospho-LCN2 (T115) antibody in neutrophil
lysates from Prkcd−/− mice than in lysates from WT littermates.
(C) The ratio of P-LCN2 (T115) to LCN2 immunoreactivity was
significantly reduced in neutrophils from Prkcd−/− compared
with Prkcd+/+ mice (n = 3) (*p < 0.05, two-tailed t test). Error bars
indicate SEM.
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at −5 and Met at +4, so Thr-115 may be preferentially
phosphorylated by PKCδ. However, the sequence lacks
a basic residue at the −3 position, and thus it is notfully conserved as a PKCδ specific phosphorylation
motif. These linear phosphorylation motifs are short
peptide sequences derived from in vitro kinase assays
using an oriented peptide library [45,46]. Thus, predic-
tions based on motifs are suggestive, but may not fully
capture the phosphorylation events in vivo. In fact, recent
studies demonstrate that PKC and PKA phosphorylate
Ser/Thr residues of substrates within sequences that do
not match known linear motifs [47]. The folding of differ-
ent parts of the substrate can create “structurally formed”
phosphorylation motifs. LCN2 exists as a monomer and
homodimer as well as heterodimer with MMP-9 [36,48].
The tertiary and quaternary structures of LCN2 may con-
tribute to the specificity of substrate phosphorylation by
PKCδ. Future studies will be needed to decipher the
mechanisms in detail.
We found that LCN2 is released from fMLP-stimulated
neutrophils in vitro and into the serum after cerebral is-
chemia (Figure 6). Previous studies demonstrate that
LCN2 is up-regulated in mouse models of spinal cord in-
jury [14] and neurodegeneration [49]. Neutrophil infiltra-
tion, expression of pro-inflammatory chemokines and
cytokines, and neuronal cell death after spinal cord injury
[14] are reduced in LCN2 null mice. We recently found
that brain injury, neurological deficits, and infiltration of
immune cells were markedly diminished in LCN2 null
mice when compared with wild type mice after stroke-
reperfusion injury [50]. Recombinant LCN2 stimulates
neutrophil migration in vitro and in vivo [51] and induces
apoptosis by sequestering intracellular iron [21,34]. More-
over, stroke patients with higher LCN2 levels in blood
plasma show higher cardiovascular mortality [17]. These
findings suggest that LCN2 is a chemoattractant for neu-
trophils and a pro-inflammatory signal induced by ner-
vous system injury. Our previous study shows that
neutrophil infiltration and brain injury are reduced in
Prkcd−/− mice after ischemic stroke [4]. Given our current
results showing that LCN2 release is reduced in Prkcd−/−
mice, the mild stroke phenotype in Prkcd−/− mice
may result in part from reduced release of LCN2.
Taken together, our results suggest that reduction of
PKCδ activation and LCN2 release might prove useful
in reducing post-ischemic inflammation and brain in-
jury after stroke.
Conclusions
Neutrophil PKCδ contributes to stroke-reperfusion injury,
but the underlying mechanisms remain to be determined.
In this report, we identified lipocalin-2 as a PKCδ sub-
strate in neutrophils using a chemical-genetics approach.
PKCδ phosphorylates lipocalin-2 at T115 and mediates
the secretion of lipocalin-2 in neutrophils. This study pro-
vides a potential mechanism for the role of PKCδ in
stroke-reperfusion injury.
Figure 6 The release of LCN2 is reduced in Prkcd−/− mice in response to fMLP and cerebral ischemia. (A) Neutrophils from Prkcd+/+ and
Prkcd−/− were stimulated with 1 μM of fMLP at 37°C for up to 120 min. LCN2 released into the media (release) and remained in neutrophils
(PMN) at different time points were detected by western blot analysis. Actin detected in neutrophils (PMN) was used as the loading control. (B)
Mouse sera collected at different time points after global cerebral ischemia were subjected to western blot analysis with anti-LCN2 and anti-IgG
antibodies. The serum of mice without ischemia was collected as a control (0). The top panel is a representative western blot. The LCN2 and IgG
protein bands were quantified by densitometry in the bottom panel. Ischemia-induced LCN2 differed by genotype [F(1,22) = 56.6; p < 0.0001] and
time [F(3,22) = 60.5; p < 0.0001] with an interaction between these factors [F(3,22) = 21.3; p < 0.0001]. * p < 0.05 compared with time 0 within
genotype. † p < 0.05 compared with Prkcd+/+ mice at the same time point (Bonferroni tests) (n = 3–5).
Figure 5 Colocalization of PKCδ and LCN2 in neutrophils. Neutrophils treated with or without fMLP were stained with specific antibodies
against PKCδ (red) and LCN2 (green). Merged images (yellow) indicate colocalization of PKCδ and LCN2. Phalloidin staining (dark blue) revealed
the reorganization of F-actin and polarization of neutrophils. An arrow indicates the front edge of the neutrophil that is enriched with F-actin.
DAPI (light blue) was used to detect nuclei. Scale bars, 10 μm.
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